23 Feb Kuur Therapeutics

Posted at 19:23h in by brady

Dan Lang, President of Cell Therapy

Oct. 13 | 5:45pm | AVROBIO Ballroom

Buffalo, NY

(NASDAQ: ATNX)

In-person Presentation

Kuur Therapeutics is developing CAR-NKT cells for treatment of cancer. Kuur has two ongoing Phase I trials and one preclinical program. Kuur was recently acquired by Athenex. Athenex is a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer. The Kuur CAR-NKT cell technology will bolster the Athenex cell therapy pipeline, which already includes its High Affinity T cell receptor program.

www.athenex.com

About the Event

The Cell & Gene Meeting on the Mesa is the sector’s foremost annual conference bringing together senior executives and top decision-makers in the industry to advance cutting-edge research into cures. Tackling the commercialization hurdles facing the cell and gene therapy sector today, this meeting covers a wide range of topics from clinical trial design to alternative payment models to scale-up and supply chain platforms for advanced therapies. The program features expert-led panels, extensive partnering capabilities, exclusive networking opportunities, and 100+ dedicated presentations by the leading publicly traded and privately held companies in the space. Attracting over 1,200 attendees – over 20% of which are C-level executives – this conference enables key partnerships through more than 3,000 one-on-one meetings while highlighting the significant clinical and commercial progress in the field.

Dates & Location

October 11-13, 2022
Carlsbad, CA

Program Organizer

By using this website you agree to accept our Privacy Policy and Terms & Conditions